Hepatitis C News

• Hepatitis D Virus Coinfection Boosts HBV Healthcare Costs Hepatitis delta virus (HDV) infection, which occurs only as a co-infection with acute hepatitis B (HBV) or a superinfection with chronic HBV, is associated with higher healthcare utilization and costs than HBV alone, a matched case-control analysis reveals.
  Reuters Health Information, December 18, 2019
• HCV Screening of Baby Boomers Continues to Lag in U.S. Safety-Net Clinics Even with help, safety-net primary care clinics serving low-income and uninsured populations in the U.S. often fall short in screening baby boomers for hepatitis C virus (HCV), as recommended by the U.S. Preventive Services Task Force, according to a new study.
  Reuters Health Information, December 02, 2019
• Improved Survival Seen in Hepatoma Patients After HCV Cure Cure of hepatitis C virus (HCV) infection with direct-acting antivirals is associated with increased survival in patients with HCV-related hepatocellular carcinoma (HCC), researchers report.
  Reuters Health Information, November 26, 2019
• Fecal Transplant Transmits Fatal Drug-Resistant E coli Infection Fecal microbiota transplant seeded resistant E coli bacteremia in two patients, one of whom died, researchers report.
  Medscape Medical News, October 31, 2019
• Hospitals Take Shot at Opioid Makers Over Treating Uninsured for Addiction A few hundred hospitals have banded together to sue drugmakers in state courts, but far more are staying on the sidelines to avoid 'unflattering attention' about their role in the opioid crisis.
  Kaiser Health News, October 30, 2019
• New Transplant Research Aims to Salvage Infected Donated Organs Retired subway and bus driver Stanley De Freitas had just celebrated his 70th birthday when he started coughing, tiring easily and feeling short of breath. He was diagnosed with pulmonary fibrosis, a severe scarring of the lungs, and put on the wait list for a transplant.
  Reuters Health Information, October 11, 2019
• Alert FDA Further Expands Approval of HCV Combo Drug Mavyret Mavyret is the first 8-week treatment approved for all treatment-naive adult and certain pediatric patients with any hepatitis C virus genotype, both without cirrhosis and with compensated cirrhosis.
  FDA Approvals, September 26, 2019
• Guideline Recommends Direct-acting Antivirals for HCV in People With Kidney Disease Patients with chronic kidney disease (CKD) should be screened for hepatitis C virus (HCV) infection, and infected individuals should be treated with direct-acting antiviral (DAA) therapy, according to the updated 2018 Kidney Disease: Improving Global Outcomes (KDIGO) clinical-practice guideline.
  Reuters Health Information, September 24, 2019
• INHSU 2019Harm Reduction Programs Lower Rate of Hep C Reinfection Hepatitis C reinfection rates are high for injection-drug users. Although rates at centers with harm-reduction programs are lower, they might not be treating high-risk populations, one expert warned.
  Medscape Medical News, September 19, 2019
• INHSU 2019Underserved Communities Receive Hep C Treatment in Jail The testing and treatment of inmates for hepatitis C can be effective, but system efficiencies, perceptions, and limits on care after release can present obstacles.
  Medscape Medical News, September 17, 2019
• INHSU 2019Indigenous Approach to Healing Influential in Hep C Care The treatment of indigenous people requires that healthcare providers consider a holistic approach to wellness, and an addiction clinic in Montreal has proven that the approach works.
  Medscape Medical News, September 16, 2019
• INHSU 2019Hepatitis C Vaccine Disappoints, Another in the Works The second-generation vaccine is being developed by one of the members of the research team that first discovered hepatitis C.
  Medscape Medical News, September 09, 2019
• HIV: Underlying Infection Still Drives Deaths in US Life expectancy for US adults infected with HIV has risen dramatically since the early 1980s, but patients are still dying from HIV-related causes rather than age-related conditions.
  Medscape Medical News, September 02, 2019
• Alert Serious Liver Injury Tied to HCV Drugs in Rare Cases, FDA Warns The US Food and Drug Agency has warned that three direct-acting antiviral drugs have been associated with rare cases of severe liver injury in patients being treated for hepatitis C virus infection.
  News Alerts, August 29, 2019
• USPSTF Recommends All Adults Receive HCV Screening The US Preventive Services Task Force has recommended that essentially all adults receive HCV screening, a major change from past risk-based recommendations.
  Medscape Medical News, August 27, 2019
• Glecaprevir-Pibrentasvir Effective for Hepatitis C After Treatment Failure The direct-acting antiviral (DAA) combination of glecaprevir and pibrentasvir is effective in patients with genotype 1 hepatitis C virus (HCV) infection after failure of treatment with sofosbuvir plus an NS5A inhibitor, according to results from a new open-label trial.
  Reuters Health Information, August 20, 2019
• Liver Disease Related to Obesity and Diabetes Rising in U.S.
  Reuters Health Information, August 14, 2019
• Combination Generic Antiviral Tablet Effective for Hep C A fixed-dose combination tablet containing the generic direct-acting antiviral drugs sofosbuvir and daclatasvir provides high rates of sustained viral response in patients with hepatitis C, according to results from the SD1000 phase 3 clinical trial in Iran.
  Reuters Health Information, July 30, 2019
• More Evidence Links Hepatitis C and Parkinson's Disease A new study reports that hepatitis C patients treated with antiviral medication were less likely to develop Parkinson's disease compared with those not receiving such therapy.
  Medscape Medical News, June 19, 2019
• Low Risk for Adverse Events With DAAs Cause for Reassurance In a nationally representative sample, patients taking direct-acting antivirals for chronic HCV infection did not experience higher rates of treatment-related adverse events than patients not taking the drugs.
  Medscape Medical News, June 07, 2019